NCT04613102View on ClinicalTrials.gov

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 1, 2020

Primary Completion Date

September 1, 2022

Study Completion Date

December 30, 2022

Conditions
Epidermolysis BullosaPainItch
Interventions
DRUG

AVCN583601 (3% Cannabidiol cream)

Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).

Trial Locations (1)

M5G1X8

The Hospital for Sick Children, Toronto

Sponsors

Collaborators (1)

Avicanna Inc
All Listed Sponsors
collaborator

Avicanna Inc

INDUSTRY

lead

Elena Pope

OTHER

NCT04613102 - The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | Biotech Hunter | Biotech Hunter